Search

Your search keyword '"Jay D. Wenger"' showing total 6 results
Start Over Author "Jay D. Wenger" Journal emerging infectious diseases
6 results on '"Jay D. Wenger"'

1. Haemophilus influenzae Serotype a Invasive Disease, Alaska, USA, 1983–2011

Author

Michael G. Bruce, Tammy Zulz, Carolynn DeByle, Ros Singleton, Debby Hurlburt, Dana Bruden, Karen Rudolph, Thomas Hennessy, Joseph Klejka, and Jay D. Wenger

Subjects
Haemophilus influenzae, H. influenzae, serotype, Alaska, invasive disease, emerging pathogen, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

Before introduction of Haemophilus influenzae type b (Hib) vaccines, rates of Hib disease in Alaska’s indigenous people were among the highest in the world. Vaccination reduced rates dramatically; however, invasive H. influenzae type a (Hia) disease has emerged. Cases of invasive disease were identified through Alaska statewide surveillance during1983–2011. Of 866 isolates analyzed for serotype, 32 (4%) were Hia. No Hia disease was identified before 2002; 32 cases occurred during 2002–2011 (p

Published
2013
Full Text
View/download PDF

2. Modeling Insights into Haemophilus influenzae Type b Disease, Transmission, and Vaccine Programs

Author

Michael L. Jackson, Charles E. Rose, Amanda Cohn, Fatima Coronado, Thomas A. Clark, Jay D. Wenger, Lisa Bulkow, Michael G. Bruce, Nancy E. Messonnier, and Thomas W. Hennessy

Subjects
Haemophilus influenzae type b, Hib, vaccines, vaccination, immunization programs, mathematical model, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

In response to the 2007–2009 Haemophilus influenzae type b (Hib) vaccine shortage in the United States, we developed a flexible model of Hib transmission and disease for optimizing Hib vaccine programs in diverse populations and situations. The model classifies population members by age, colonization/disease status, and antibody levels, with movement across categories defined by differential equations. We implemented the model for the United States as a whole, England and Wales, and the Alaska Native population. This model accurately simulated Hib incidence in all 3 populations, including the increased incidence in England/Wales beginning in 1999 and the change in Hib incidence in Alaska Natives after switching Hib vaccines in 1996. The model suggests that a vaccine shortage requiring deferral of the booster dose could last 3 years in the United States before loss of herd immunity would result in increasing rates of invasive Hib disease in children

Published
2012
Full Text
View/download PDF

3. Rapid Assessment Tool for Haemophilus influenzae type b Disease in Developing Countries

Author

Daniel R. Feikin, Christopher B. Nelson, James P. Watt, Ezzeddine Mohsni, Jay D. Wenger, and Orin S. Levine

Subjects
Haemophilus influenzae type b, meningitis, pneumonia, conjugate vaccines, developing countries, research, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

Haemophilus influenzae type b (Hib) still causes a substantial number of deaths among children in developing countries, despite the availability of effective conjugate vaccines. A major obstacle in developing a Hib vaccine has been limited awareness about the impact of Hib disease. A tool was developed to estimate the national rates of Hib meningitis and pneumonia by assessing retrospective local data over 7 to 10 days. Data from 11 countries in Africa, the Middle East, and Asia were studied and showed rates of Hib meningitis from >50 cases per 100,000 children >5 years in Ghana and Uganda to

Published
2004
Full Text
View/download PDF

5. Facility-Associated Release of Polioviruses into Communities—Risks for the Posteradication Era

Author

Jay D. Wenger, Ananda S Bandyopadhyay, Jacqueline Fournier-Caruana, Jeffrey Partridge, John F. Modlin, Michel Zaffran, Harpal Singh, and Roland W. Sutter

Subjects
Microbiology (medical), Epidemiology, viruses, 030231 tropical medicine, polio, lcsh:Medicine, Biohazard Release, macromolecular substances, Vaccine Production, medicine.disease_cause, reemerging infectious disease, Global Health, complex mixtures, lcsh:Infectious and parasitic diseases, containment, 03 medical and health sciences, 0302 clinical medicine, Poliomyelitis eradication, Environmental health, medicine, accidental release, Animals, Humans, lcsh:RC109-216, 030212 general & internal medicine, Disease Eradication, Poliovirus type, laboratory infections, poliovirus, Transmission (medicine), business.industry, Historical Review, Poliovirus, lcsh:R, Facility-Associated Release of Polioviruses into Communities—Risks for the Posteradication Era, medicine.disease, Poliomyelitis, Poliovirus Vaccine, Inactivated, Infectious Diseases, vaccine-preventable diseases, Poliovirus Vaccine, Oral, Inactivated Poliovirus Vaccine, Vaccine-preventable diseases, business, Laboratories, biological
Abstract

The Global Polio Eradication Initiative continues to make progress toward the eradication target. Indigenous wild poliovirus (WPV) type 2 was last detected in 1999, WPV type 3 was last detected in 2012, and over the past 2 years WPV type 1 has been detected only in parts of 2 countries (Afghanistan and Pakistan). Once the eradication of poliomyelitis is achieved, infectious and potentially infectious poliovirus materials retained in laboratories, vaccine production sites, and other storage facilities will continue to pose a risk for poliovirus reintroduction into communities. The recent breach in containment of WPV type 2 in an inactivated poliovirus vaccine manufacturing site in the Netherlands prompted this review, which summarizes information on facility-associated release of polioviruses into communities reported over >8 decades. Successful polio eradication requires the management of poliovirus containment posteradication to prevent the consequences of the reestablishment of poliovirus transmission.

Published
2019

6. Haemophilus influenzae Serotype a Invasive Disease, Alaska, USA, 1983–2011

Author

Dana Bruden, Debby Hurlburt, Joseph Klejka, Ros Singleton, Michael G. Bruce, Thomas W. Hennessy, Tammy Zulz, Carolynn DeByle, Karen Rudolph, and Jay D. Wenger

Subjects
Serotype, Pediatrics, Epidemiology, lcsh:Medicine, medicine.disease_cause, Disease Outbreaks, Haemophilus influenzae, Alaska Native people, H. influenzae, Public Health Surveillance, serotype, emerging pathogen, bacteria, Child, Epiglottitis, Geography, biology, Incidence, Incidence (epidemiology), meningitis, Middle Aged, Vaccination, Infectious Diseases, coccobacillus, Child, Preschool, invasive disease, Meningitis, Adult, Microbiology (medical), medicine.medical_specialty, Haemophilus Infections, Adolescent, pericarditis, History, 21st Century, lcsh:Infectious and parasitic diseases, Young Adult, Hia, medicine, pneumonia, Humans, lcsh:RC109-216, bacteremia, cellulitis, Serotyping, Hib, septic arthritis, epiglottitis, Bacterial disease, business.industry, Research, lcsh:R, Infant, otitis media, History, 20th Century, medicine.disease, biology.organism_classification, United States, Coccobacillus, business, Alaska, Multilocus Sequence Typing
Abstract

Before introduction of Haemophilus influenzae type b (Hib) vaccines, rates of Hib disease in Alaska's indigenous people were among the highest in the world. Vaccination reduced rates dramatically; however, invasive H. influenzae type a (Hia) disease has emerged. Cases of invasive disease were identified through Alaska statewide surveillance during 1983-2011. Of 866 isolates analyzed for serotype, 32 (4%) were Hia. No Hia disease was identified before 2002; 32 cases occurred during 2002-2011 (p

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results